BIOTRICITY INC. (BTCY): Nasdaq/NYSE listing notice — Biotricity faces Nasdaq delisting for missing annual meeting; closes $354k private placement

BIOTRICITY INC.

Nasdaq notified Biotricity on May 1, 2024 of non-compliance with annual meeting rule; additional delisting basis.
Company must respond to Nasdaq Hearings Panel by May 8, 2024; intends to hold meeting as soon as practicable.
On April 30, 2024, closed second tranche of private placement: 39 Series B Preferred shares for $354,545.
Registration Rights Agreement filed; failure to file or obtain effectiveness triggers 100,000 common shares per event.

item 3.01 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BIOTRICITY INC. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5620(a)

Exact text from the filing

May 1, 2024, Biotricity Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) stating that it is not in compliance with the Nasdaq Listing Rule 5620(a) (the “Rule”) requiring that the Company hold an annual meeting of stockholders within 12 months of the end of its fiscal year. The notification received has no immediate effect on the Company’s continued listing on the Nasdaq Capital Market, subject to its compliance with the other continued listing requirements. In the letter dated May 1, 2024, Nasdaq notified the Company that this serves as an additional basis for del

View on SEC.gov

88 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BIOTRICITY INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-017744

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.